8-K - Avalon GloboCare Corp. (0001630212) (Filer)

8-K - Avalon GloboCare Corp. (0001630212) (Filer)

8-K - Avalon GloboCare Corp. (0001630212) (Filer)

8-K - Avalon GloboCare Corp. (0001630212) (Filer)

8-K - Avalon GloboCare Corp. (0001630212) (Filer)

8-K - Avalon GloboCare Corp. (0001630212) (Filer)

8-K - Avalon GloboCare Corp. (0001630212) (Filer)

8-K - Avalon GloboCare Corp. (0001630212) (Filer)

8-K - Avalon GloboCare Corp. (0001630212) (Filer)

DEF 14A - Avalon GloboCare Corp. (0001630212) (Filer)

FREEHOLD, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it has appointed Dr. Charles Cavo to its Scientific and Clinical Advisory Board. Dr. Charles Cavo is the co-founder and Chief Medical Officer of Pounds Transformation, founded to help patients successfully reach their health and wellness goals through a combination of medical and lifestyle interventions related to nutrition and exercise. Dr. Cavo specialized in family medicine as an OBGYN at the Hospital of Central Connecticut and was drawn to the challenge of the obesity epid

Celebration, FL, May 21, 2024 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) ("La Rosa" or the "Company"), a holding company for five agent-centric, technology-integrated, cloud-based, multi-service real estate segments, today announced that it has appointed Lourdes Felix to its Board of Directors. Ms. Felix was also appointed to serve as the Chairperson of the Audit Committee and as a member of the Board's Compensation Committee and Nominating and Corporate Governance Committee. Ms. Lourdes Felix is an accomplished entrepreneur and corporate finance executive with 30 years of combined experience in capital markets, public accounting and in the private sector. She currently

FREEHOLD, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC ("LSM"), has acquired Merlin Medical Supply ("MMS"), a profitable, well-established Home Medical Equipment ("HME") and Durable Medical Equipment ("DME") company providing acute and non-acute medical supplies in Ventura County, California. Additionally, LSM has acquired Leading Edge Innovations, LLC from the same owner. Leading Edge Innovations owns the GeeWhiz External Condom Catheter, a patented, FDA-registered, in-market, male incontine

FREEHOLD, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC ("LSM"), has acquired DE Laboratory LLC ("DE Labs"), which expands its penetration within Texas and provides significant potential growth opportunities for the combined company. Avalon owns a 40% interest in LSM. DE Labs is a CLIA-certified and COLA-accredited laboratory located in Houston, Texas that offers a wide range of high-quality testing, including drug testing, genetic testing, urinary testing and COVID-19 PCR testing. LSM is no

FREEHOLD, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that the Company received notice from The Nasdaq Stock Market ("Nasdaq") on November 19, 2024, notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Rule 5550(a)(2). David Jin, M.D., Ph.D., CEO of Avalon GloboCare, stated, "Regaining compliance reflects our commitment to our shareholders and reinforces our focus on strong corporate governance. We remain resolute in our mission to drive sustainable long-term value for both our share

FREEHOLD, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and laboratory services, today announced the launch of the "BrAce for Impact" affiliate marketing program for KetoAir™, a handheld breathalyzer device equipped with AI-enabled software and Hot App shareable technology, specifically designed for ketogenic health monitoring. The "BrAce for Impact" affiliate marketing program was developed in response to demand from attendees at the Hack Your Health Conference (Austin, May 31-June 2, 2024) and the Keto Pa-LOU-za Conference (Louisville, KY, Oct. 11-13, 2024). The program offers an

FREEHOLD, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it has appointed Dr. Charles Cavo to its Scientific and Clinical Advisory Board. Dr. Charles Cavo is the co-founder and Chief Medical Officer of Pounds Transformation, founded to help patients successfully reach their health and wellness goals through a combination of medical and lifestyle interventions related to nutrition and exercise. Dr. Cavo specialized in family medicine as an OBGYN at the Hospital of Central Connecticut and was drawn to the challenge of the obesity epid

FREEHOLD, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it entered into a memorandum of understanding (the "MOU") with Qi Diagnostics Limited ("Qi Diagnostics"), a nanosensor-based diagnostic technologies company, to explore a proposed strategic collaboration to co-develop a VOC (volatile organic compound) nanosensor-based point-of-care cannabis breathalyzer. The MOU provides Avalon with an exclusivity period of 120 days (the "Exclusivity Period"), during which Avalon intends to negotiate with Qi Diagnostics and enter into a definitive ag

FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it will effect a 1-for-15 reverse split ("reverse split") of its common shares that will become effective on October 28, 2024. The Company expects that the reverse stock split will allow the Company to regain compliance with the $1.00 minimum bid price requirement of the Nasdaq Capital Market. Avalon GloboCare's common shares will continue to trade on Nasdaq under the symbol "ALBT" and will begin trading on a split-adjusted basis when the market opens on October 28, 2024. The new

FREEHOLD, N.J., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and laboratory services, today announced its participation as an event sponsor at the Keto Pa-LOU-za 2024 Conference, taking place October 11-13, 2024, at the Galt House Hotel in Louisville, KY. Avalon will use the event to showcase the KetoAir™ breathalyzer device, a handheld device designed to monitor ketosis via breath analysis. Conference attendees will have the opportunity to see live demonstrations of the device and purchase it, along with related accessories, directly on-site. "We are excited to partner with the Ket

FREEHOLD, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that Laboratory Services MSO, LLC ("LSM") has launched a direct-to-consumer and non-invasive DNA test in the U.S. that tests for potential predisposition to opioid dependence. To purchase or find out more information, please visit www.dna4addiction.com. Avalon owns a 40% equity interest in LSM. The opioid abuse epidemic continues to devastate communities across America, representing a significant public health crisis. According to the Centers for Disease Control and P

FREEHOLD, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced the official launch of online sales for the KetoAir™ breathalyzer device and related accessories in the U.S. The products are now available at www.ketoair.us. KetoAir™ is a breathalyzer featuring Hot App shareable technology with AI-enabled software, specifically engineered for ketogenic health management (United States FDA registration number: 3026284320). By leveraging the nano-sensor-based technology and AI algorithms, the KetoAir™ breathalyzer is designed not only

FREEHOLD, N.J., June 20, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today provided an update on the launch of the KetoAir™ breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference that was held on May 31 to June 2, 2024 in Austin, Texas. "We're excited to report the successful launch of KetoAir™ breathalyzer sales in the U.S. at the Hack Your Health conference," stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. "The booth at the event attracted a diverse group o

FREEHOLD, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it received a notice (the "Notice") on May 22, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") because the Company has not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 (the "Quarterly Report") with the Securities and Exchange Commission (the "SEC"). The Notice has no immediat

Shares of Mainz Biomed N.V. (NASDAQ:MYNZ) rose sharply in today's pre-market trading after the company announced submission for the FDA Breakthrough Device Designation for its next generation CRC screening test. Mainz Biomed shares jumped 16% to $0.5534 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Pineapple Energy Inc. (NASDAQ:PEGY) rose 85% to $2.22 in pre-market trading. Pineapple Energy engaged Conduit Capital to provide structural internal support, staffing, and assistance with capital raising activities. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) shares rose 43.5% to $13.26 in pre-market trading after gaining 127% on Mon

Shares of Core & Main Inc (NYSE:CNM) fell sharply during Tuesday's session after the company reported mixed first-quarter financial results. Core & Main posted quarterly earnings of 49 cents per share, missing market expectations of 52 cents per share. The company's quarterly sales came in at $1.74 billion versus estimates of $1.72 billion, according to data from Benzinga Pro. Core & Main shares dipped 11.4% to $49.77 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers MicroAlgo Inc (NASDAQ:MLGO) shares jumped 284% to 5.99 after the company announced that it will jointly establish a micro-consciousness quantum research center with WiMi. Sobr S

U.S. stocks traded lower this morning, with the Dow Jones falling more than 70 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.20% to 38,493.85 while the NASDAQ fell 0.22% to 16,790.91. The S&P 500 also fell, dropping, 0.24% to 5,270.55. Check This Out: Top 3 Financial Stocks You’ll Regret Missing This Quarter Leading and Lagging SectorsReal estate shares rose by 0.2% on Tuesday. In trading on Tuesday, energy shares fell by 1.7%. Top Headline Donaldson Company Inc (NYSE:DCI) reported better-than-expected third-quarter earnings and raised its FY24 guidance. Sales increased 6.0% Y/Y to $927.9 million beating the consensus of $915.8 million, l

Shares of Healthequity Inc (NASDAQ:HQY) rose sharply in today's pre-market trading as the company reported better-than-expected first-quarter financial results. The company reported quarterly earnings of 80 cents per share which beat the analyst consensus estimate of 66 cents, according to data from Benzinga Pro. HealthEquity issued strong FY25 earnings guidance and also issued FY25 revenue guidance with its midpoint above expectations. Healthequity shares jumped 5.9% to $85.98 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers MicroAlgo Inc (NASDAQ:MLGO) rose 209.5% to $4.83 in today's pre-market trading. WiMi Hologram Cloud a